EU guideline revamp to clarify pediatric drug development rules
This article was originally published in SRA
The European Commission is revising its 2008 guideline on pediatric investigation plans (PIPs) to bring it more into line with actual practice1. The move is expected to clarify the rules in a number of areas and is seen as an important step in encouraging more companies to pursue pediatric drug development programs.
You may also be interested in...
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.